Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

Vast Therapeutics, a clinical-stage life science company, today announced that the U.S. Food and Drug Administration has ...

This study cohort was made up of 71.3% U.K. patients with bronchiectasis. Referral to pulmonary rehabilitation was presented to 19.6% of patients. Prior to being diagnosed with bronchiectasis ...

Brensocatib, if approved, would be the first available treatment specifically targeting bronchiectasis, a chronic lung disease that currently has no FDA-approved therapies in the U.S. The drug is ...

According to PROMIS-I data published in the journal of The Lancet Respiratory Medicine showed that individuals with ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for chronic lung disease bronchiectasis in the US. The regulator has set a ...

Shares in Insmed have rocketed after the biotech reported positive results in a highly-anticipated clinical trial of brensocatib in the respiratory disorder bronchiectasis. The phase 3 trial ...

The Bronchiectasis and NTM Association has accepted 27 Care Center and six Clinical Associate Center sites in 23 states and the District of Columbia into the new Bronchiectasis and NTM Care Center ...

Considering taking supplements to treat bronchiectasis? Below is a list of common natural remedies used to treat or reduce the symptoms of bronchiectasis. Follow the links to read common uses ...

The Bronchiectasis and NTM Association has accepted UC San Francisco (UCSF) into its Bronchiectasis and NTM Care Center Network (CCN), recognizing UCSF’s dedication to providing high-quality medical ...

Find effective medications for 'Bronchiectasis treatment right here!' This page is a trusted source for both professionals and patients, detailing brand-name and generic options designed to manage ...